Konsistensi Respon Imun Humoral (IgG) SARS-CoV-2 Pasca Vaksinasi SARS-CoV-2 pada Tenaga Kesehatan

Abror Irsan✉, Mardhia Mardhia, Ambar Rialita
DOI: https://doi.org/10.25077/mka.v45.i2.p118-125.2022

Abstract

Tujuan: penelitian ini bertujuan untuk mengetahui respon humoral antibodi IgG pada tenaga kesehatan setelah dua dosis vaksinasi coronavirus disease 2019 (COVID-19); Metode: Penelitian merupakan studi deskriptif dengan desain potong lintang pada bulan Juli hingga Desember 2021 di Rumah Sakit Anton Soedjarwo, Pontianak. Responden merupakan tenaga kesehatan yang bertugas di Instalasi Gawat Darurat rumah sakit yang diambil secara consecutive sampling. Deteksi dan pengukuran kadar anti-SARS-CoV-2 IgG dilakukan dengan metode Chemiluminescent Microparticle Immunoassay (CMIA) dengan target protein S-RBD. Pemeriksaan dilakukan pada enam bulan setelah dosis ke-dua vaksin; Hasil: Total responden adalah 23 orang, dengan jumlah persentase laki-laki dan perempuan yaitu 47,83% dan 52,17% dengan rerata usia 28,9 tahun. Hasil kadar respon humoral antibodi IgG setelah enam bulan vaksinasi dosis ke-dua91,30% menunjukkan hasil reaktif/seropositif dengan nilai median kadar antibodi IgG 1951,5 AU/ml; Kesimpulan: Respon humoral antibodi IgG SARS-CoV-2 responden mayoritas menunjukkan hasil positif dengan rentang nilai yang bervariasi dan diharapkan dapat menjadi dasar apakah memerlukan vaksinasi ulangan atau booster ke depannya.

Kata kunci: vaksin COVID-19; antibodi IgG; respon humoral

Keywords

Medicine; Public health; Clinical sciences

Full Text:

PDF

References

Syaifuddin AI. Over a dozen vaccinated doctors dead as Indonesia ’ s virus cases surge [Internet]. 2021. p. 1–2. Available from: https://medicalxpress.com/news/2021-06-dozen-vaccinated-doctors-dead-indonesia.html

Badan Nasional Penanggulangan Bencana. Situasi Virus Corona – Covid19. 2020. 2020.

Ing EB, Xu QA, Salimi A, Torun N. Physician deaths from corona virus (COVID-19) disease. Occup Med (Chic Ill). 2020;70(5):370–4.

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, et al. Development of an Inactivated Vaccine Candidate for SARS-CoV-2. Science (80- ). 2020;369:77–81.

Ndzouboukou J-LB, Zhang Y, Lei Q, Lin X, Yao Z jie, Fu H, et al. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. Curr Med Sci. 2021;41(6):1081–6.

Syahniar R, Purba MB, Bekti HS, Mardhia M. Vaccines against Coronavirus Disease : Target Proteins , Immune Responses , and Status of Ongoing Clinical Trials. J Pure Appl Microbiol. 2020;14(December):2253–63.

Jeyanathan M, Afkhami S, Smaill F, Miller MS, Lichty BD, Xing Z. Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020 Oct;20(10):615–32.

Uysal EB, Gümüş S, Bektöre B, Bozkurt H, Gözalan A. Evaluation of antibody response after COVID-19 vaccination of healthcare workers. J Med Virol. 2021;(October).

Mahendradhata Y, Andayani NLPE, Hasri ET, Arifi MD, Siahaan RGM, Solikha DA, et al. The Capacity of the Indonesian Healthcare System to Respond to COVID-19. Front Public Heal. 2021;9(July):1–9.

Tanis J, Vancutsem E, Piérard D, Weets I, Bjerke M, Schiettecatte J, et al. Evaluation of four laboratory-based SARS-CoV-2 IgG antibody immunoassays. Diagn Microbiol Infect Dis. 2021;100(1).

English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG. Performance of the abbott sars-cov-2 igg ii quantitative antibody assay including the new variants of concern, voc 202012/v1 (united kingdom) and voc 202012/v2 (south africa), and first steps towards global harmonization of COVID-19 antibody methods. J Clin Microbiol. 2021;59(9):1–10.

Manalac J, Yee J, Calayag K, Nguyen L, Patel PM, Zhou D, et al. Evaluation of Abbott anti-SARS-CoV-2 CMIA IgG and Euroimmun ELISA IgG/IgA assays in a clinical lab. Clin Chim Acta [Internet]. 2020;510(September):687–90. Available from: https://doi.org/10.1016/j.cca.2020.09.002

Banga Ndzouboukou JL, Zhang Y di, Lei Q, Lin X song, Yao Z jie, Fu H, et al. Human IgM and IgG Responses to an Inactivated SARS-CoV-2 Vaccine. Curr Med Sci. 2021;1–8.

Altawalah H. Antibody responses to natural sars-cov-2 infection or after covid-19 vaccination. Vaccines. 2021;9(8):1–14.

Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. N Engl J Med. 2021;385(10):875–84.

Doria-Rose N, Suthar MS, Makowski M, O’Connell S, McDermott AB, Flach B, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021;384(23):2259–61.

Murin CD, Wilson IA, Ward AB, Biology C, Jolla L, Discovery I, et al. Antibody responses to viral infections: a structural perspective across three different enveloped viruses Charles. Nat Microbiol. 2019;4(5):734–47.

Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: From structure to effector functions. Front Immunol. 2014;5(OCT):1–17.

Azak E, Karadenizili A, Uzuner H, Karakaya N, Canturk NZ, Hulagu S. Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection. Int J Infect Dis. 2021;113:58–64.

Bayram A, Demirbakan H, Karadeniz PG, Erdoğan M, Koçer I. Quantitation of antibodies against SARS‐CoV‐2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93(9):5560–7.

Röltgen K, Boyd SD. Antibody and B cell responses to SARS-CoV-2 infection and vaccination. Cell Host Microbe. 2021;29(7):1063–75.

Desai D, Khan AR, Soneja M, Mittal A, Naik S, Kodan P, et al. Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study. Lancet Infect Dis [Internet]. 2021;3099(21). Available from: http://dx.doi.org/10.1016/S1473-3099(21)00674-5

Mahase E. Covid-19: Do vaccines work against omicron-and other questions answered. BMJ [Internet]. 2021;375(December):n3062. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34893476



Bookmark and Share
-->